Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Bought by Fmr LLC

Fmr LLC grew its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 17.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,512,300 shares of the company’s stock after purchasing an additional 830,000 shares during the period. Fmr LLC owned approximately 0.16% of Oruka Therapeutics worth $106,883,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after buying an additional 1,572,853 shares during the period. Franklin Resources Inc. purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at about $17,661,000. Geode Capital Management LLC increased its stake in shares of Oruka Therapeutics by 2,348.6% during the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company’s stock worth $6,643,000 after acquiring an additional 328,434 shares during the period. Wellington Management Group LLP raised its holdings in Oruka Therapeutics by 15.8% during the fourth quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after purchasing an additional 12,952 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics in the fourth quarter valued at about $303,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Insider Activity at Oruka Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the transaction, the insider now owns 4,148,428 shares in the company, valued at $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have purchased 98,339 shares of company stock valued at $1,128,456. 22.67% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ORKA shares. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research started coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Stock Up 6.0 %

Shares of ORKA stock opened at $8.14 on Tuesday. The stock has a market cap of $304.77 million, a P/E ratio of -1.30 and a beta of 0.47. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The business has a fifty day simple moving average of $10.37 and a 200-day simple moving average of $17.70.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.19. On average, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.